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Available online 20 March 2016The present study aimed to prepare mucoadhesive microparticles of furazolidone (antimicrobial agent) using
chitosan as a mucin adsorptive polymer and spray drying technology. This study recognized the potential use
of furazolidone to directly target stomach (for example against Helicobacter pylori in order to afford low resistant
anti helicobacter agent as compared to commonly used antibiotics). Therefore, local mucoadhesive drug delivery
systems in the stomach by using easily tailored approach of spray drying was used in this study. In order to get
sufﬁcient drug release for effective period of time at the pH conditions of stomach under the inﬂuence of
H. pylori, the study was conducted at two different pH levels (1.3 and 4.5). The amount of glutaraldehyde
(GTA) as a crosslinking agent was also studied to get appropriate particles size, and drug release. By increasing
the amount of GTA, particles size and the release were decreased at pH 1.3 as well as at pH 4.5. The pH of the
media also showed signiﬁcant effect on the drug release, i.e. by decreasing the pH the release was increased.
Similarly, crosslinking agent showed negative effect on mucin adsorption. However, by reducing the pH from
4.5 to 1.3 themucin adsorptionwas also reduced; thereforemucoadhesion increases at pH 4.5which is desirable
for targeting H. pylori as normal stomach pH is expected to increase by the effect of H. pylori. Hence, the data of
this research can be considered for future in vivo study.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Drug release1. Introduction
Resistance of Helicobacter pylori against most commonly practiced
antibiotics clarithromycin and metronidazole posing serious therapeu-
tic problems and resistance may be changed with time because of sec-
ondary resistance [1]. According to Health Protection Agency 20–63%
resistance to metronidazole and 4.4–11% to clarithromycin is reported
in the UK and in some urban areas it can reach up to 65%. There is no
other slandered therapy recommended in case of failure [2]. Therefore,
there is intense need to develop new antibiotic for H. Pylori with mini-
mum resistance. A number of anti-H. pylori agents were being investi-
gated and new strategies are currently under testing to minimize
resistance and to make the drug available. Furazolidone emerges as po-
tential candidate for therapeutic consideration with low documented
resistance. In addition to use of low resistance antimicrobial agent, the
availability of drug on site may also be considered as a promising ap-
proach to encounter H. pylori. There are a number of ways that can pro-
vide high concentration in gastric mucosa to enhance microorganismepartment of Pharmacy, Health
Elkordy).eradication [3]. The diffusion of drug from gastric lumen after its adhe-
sion to mucus layer to encounter H. pylori which resides deep in the
stomach could be considered as oral site-speciﬁc delivery system [4].
There are a number of approaches for development ofmucoadhesive
drug delivery system. A large literature shows the preparation of
sustained release microparticles by using spray drying approach [5,6].
A number of studies revealed that initial parameter of spray drying
could inﬂuence the characteristics of ﬁnished product for example par-
ticles size increases by increasing the feed rate [7]. However, increase in
inlet temperature has adverse an effect on particle size [8]. Spray drying
technique for developing mucoadhesive microsphere is simple, quick
and straight forward approach which can be used to optimize the
number of parameters that could affect the characteristics of ﬁnal
formulations.
Chitosans are biodegradable, linear amino polysaccharides with a
random distribution of b-1,4-N-acetyl-D-glucosamine and D-glucos-
amine. They are derived from the biopolymer chitin and are used in
food preparations. Hence, they present safety, biocompatibility and in
some studies anti-ulcer activity [9] and therefore chitosan could be con-
sidered asmost appropriate polymer for development of mucoadhesive
microparticles by using spray drying. Chitosan contain OH and NH2
groups which are responsible for hydrogen bonding and furthermore
176 M.I. Alam et al. / Powder Technology 295 (2016) 175–179being cationic polymer provide strong electrostatic interaction with
negatively charged mucus surface [10].
The purpose of the current study was development of spray dried
mucoadhesive microparticles of furazolidone with the ultimate aim to
modulate mucoadhesion and local drug release on gastric mucosal sur-
face. To the best of our knowledge, there are no publications available
for formulation of furazolidone in mucoadhesive systems using spray
drying technology.
2. Materials
Furazolidone, glutaraldehyde (GTA) and chitosan were purchased
from sigma Aldrich. Mucin Type I (from bovine submaxillary glands),
Schiff reagent periodic acid and pepsin (partially puriﬁed from porcine
stomach) were purchased from sigma Aldrich. Trisma buffer and cali-
bration particles CPC (300, 400, 1000 and 2000 nm) were purchased
from Izon Science, Oxford UK. All other chemicals, reagents and solvents
used were of either analytical or pharmaceutical reagent grade.
3. Preparation of microparticles
Chitosan microparticles were prepared by using spray dryer (Bucci
B-290 Switzerland) technique. 0.1% of chitosan (1 mg per ml) in 15 ml
of 1% acetic acid solutionwas prepared by continues stirring for 6 h. Dif-
ferent volumes of 1% glutaraldehyde as crosslinking agent were added
to make different formulations listed in Table 1. For drug loading
10 mg or 15 mg of furazolidone was suspended in distilled water
(~85 ml) or dissolved in acetonitrile/distilled water mixture (3:82) in
different formulations as shown in Table 1. The volume to be spray
dried was 100 ml per batch.
The applied spray drying conditions were inlet temperature of
160 °C, pressure of 4 bars, ﬂow rate of 2 ml/min, aspirator 100% and
pump at 65%. The resultant dry powder was collected via cyclone
separator in a dry collection bottle.
4. Characterization of chitosan microsphere
Microspheres were characterized by particle size analysis,
mucoadhesion, in vitro drug release, process yield and drug content.
4.1. Drug content
The powder collected contains drug and polymer was dissolved in
speciﬁed amount of distilled water tomake suspension. 1 ml of suspen-
sionwas centrifuged. Acetonitrile and acetic acidwas added to pellets to
dissolve the drug and chitosan and then 0.5 ml of the solution was sub-
jected to HPLC (as discussed below). The concentration was calculated
from AUC by using HPLC standard calibration curve of furazolidone.
4.2. HPLC method
The HPLC analysis was carried out using Agilent Chem Station LC-
DAD, with UV detector (Agilent technologies, (76,337), Germany). The
column (4.60 mm × 150 cm) was used for analysis. Gradient system
of mobile phases consisted of 0.5% phosphoric acid water with pH 7.4
and acetonitrile, ﬂow rate of 1 ml/min was applied. Temperature
of the column was maintained at 30 °C and wavelength used was
320 nm. Retention time was determined at 4.388 min.Table 1
Composition of furazolidone-chitosan formulations prepared by spray drying.
Formulation code Chitosan (0.1%) Drug (mg) Glutaraldehyde
F1 15 mg 10 2 mg
F2 15 mg 15 4 mg
F3 15 mg 15 6 mg4.3. Process yield
The yield recovered from spray dryingwas calculated by the formula
¼ powder recovered mgð Þ
Total amounts of drug; glutaraldehyde and chitosan mgð Þ  100:
4.4. Particle size analysis
Particle sizewas determined by using Izon qNano particle sizer (Izon
Science Ltd. NewZealand) inwhichparticles sizewasmeasured in terms
of current block that is proportional to the diameter of particle size. Two
different nanopores (1000 and 2000) were selected for each formula-
tion to get more reliable data. Selection of nanopores for each formula
was based on the expected size and particle size distribution.
4.5. Muco-adsorption
For mucin adsorption, calorimetric method was used in which peri-
odic acid and Schiff reagent were used for the determination of remain-
ing free mucin after its adsorption on the chitosan microparticles. 0.1 g
of sodium metabisulfate was added to every 6 ml of Schiff reagent and
incubated at 37 °C till it turned into pale yellow color. 10 μl of 50% peri-
odic acid was added to 7 ml of 7% acetic acid to make periodic acid re-
agent. Periodic acid reagent (0.2 ml) was added to mucin samples and
incubated at 37 °C for 2 h followed by addition of 0.2ml of Schiff reagent
at room temperature (~22 °C) and kept for 30 min. Absorbance was
measured at 555 nm by UV/visible spectrophotometer (Model M501,
Camspec, Biochrom, UK). The concentration of free mucin was deter-
mined by using standard calibration curve of mucin (Type-I from
sigma Aldrich). Standard solutions for calibration curve (0.1, 0.25, 0.5,
0.75 and 1 mg/2 ml) were made and absorbance was measured by
UV/visible spectrophotometer at 555 nm.
Mucin concentration of 1 mg/2 ml was prepared and 2 ml of micro-
particle (F1 to F3) suspensions (in pH 1.3 or pH 4.5) containing different
amount of chitosan and crosslinking agent were centrifuged. Superna-
tant was discarded and pellets of F1–F3 were dispersed in to standard
mucin solution separately and vortexed for 5 min and later analyzed
for free mucin concertation at predetermined time intervals (1.5, 3,
4.5 and 6 h). Separate Eppendorf tubes with mucin and microparticles
formulations were used for each time interval. The dispersion was
centrifuged at 4000 rpm for 5 min, supernatant was used for the
measurement of free mucin by using the method stated above.
4.6. In-vitro drug release
Modiﬁed dispersion method stated by [11] was used to perform in-
vitro dissolution. Release was determined, in triplicate, in water bath at
37 °C for F1–F3 formulations at (0, 0.5, 1, 1.5, 2, 3, 4 and 5 h) at pH 1.3
and pH 4.5; hence the study was conducted on two different pH levels,
one of themwas pH condition thatmimics post proton pump inhibitors
microenvironment in stomach in the presence of H. pylori and the other
pH was using natural stomach pH. In this release study method, micro-
spheres equal to 2 mg of the drug was centrifuged at 4000 rpm for
5 min. Supernatant was discarded and pellets were transferred to new
vials without disturbing the yellow colored precipitated drug at the
bottom. Pellets were washed with water three times and suspended(1%) Solvent used Total volume (ml)/batch
Acetonitrile/distilled water (3:82) 100
Acetonitrile/distilled water (3:82) 100
Distilled water 100
Table 2
Particle size, percent drug content and process yield of spray dried furazolidone-chitosan
formulations. For formulation composition refer to Table 1.
Formula Nanopore
(μm)
Particle size (μm) Drug
content
(%)
Process
yield
(%)Maximum Minimum mode mean
F1 1.000 3.640 0.987 1.137 1.616 60.0 49.2
2.000 4.248 1.866 2.116 2.377
F2 1.000 2.195 0.723 0.939 1.163 66.6 57.3
2.000 4.240 1.688 1.818 1.860
F3 1.000 2.407 0.670 0.805 0.990 51.5 44.3
2.000 3.386 1.274 1.424 1.729
Table 3
Correlation coefﬁcient squared of release kinetic models for furazolidone-chitosan formu-
lations at different pH levels. For formulation composition refer to Table 1.
Formulations pH 1.3 pH 4.5
Zero order r2 First order r2 Zero order r2 First order r2
F1 0.980 0.971 0.991 0.988
F2 0.992 0.989 0.997 0.977
F3 0.996 0.980 0.997 0.990
177M.I. Alam et al. / Powder Technology 295 (2016) 175–179in 10 ml of SGF at the desired pH. After speciﬁed time 0.5 ml of sam-
ple was withdrawn from and replaced by equal volume of fresh SGF
which was ﬁltered by 0.2 μm ﬁlter and then analyzed by HPLC
analysis.Fig. 1. SEM photomicrographs of mucoadhesive spray dried furazolid4.7. Particle morphology
Scanning electron photomicrographs of all microsphereswere taken
bymicroscope (Hitachi S3000N,HitachiHigh-Technologies UK-Electron
Microscopes, Wokingham Berkshire, UK). Small amount of each sample
was attached to a 15mmdiameter aluminum specimen stub using dou-
ble sided carbon adhesive tabs (Mikrostik adhesive, Agar Scientiﬁc), and
the powder samples were sputter-coated with a thin layer of gold/pal-
ladium mixture to allow them to be electrically conductive. This was
carried out using a Quorum Technology (Polaron range) SC760, where-
by the samples are exposed to argon atmosphere at 10 Pa. The samples
are coated at a process current of 18–20mA for 2 × 105 s,with a turning
through 180° in between.
4.8. Statistical analysis
The statistical software SPSS 21 (SPSS Inc., Chicago, USA) was
applied to carry out the statistical analysis by using ANOVA test
and Post hoc multiple comparisons were applied when necessary. A
p value of b0.05 was considered signiﬁcant.
5. Results and discussion
5.1. Characteristics of microparticles
Characteristics of microparticles prepared by spray drying method
are listed in Table 2. Particle size ranges from1.0 μmto2.4 μm.By addingone microparticles. For formulation composition refer to Table 1.
Fig. 2.Mucin adsorption of furazolidone-chitosan microparticle formulations at a) pH 4.5
and b) pH 1.3. Glutaraldehyde is abbreviated byGTA. For formulation composition refer to
Table 1.
178 M.I. Alam et al. / Powder Technology 295 (2016) 175–179the cross linking agent particle size was decreased which is in agree-
ment with study conducted by [10,12]. Formulation F3 with highest
amount of glutaraldehyde having particle size of 0.805/1.424 μm
(mode value, Table 2) however it increased by decreasing the amount
of glutaraldehyde. (See Table 3.)
According to study conducted [13] increase in viscosity of the solu-
tion, resulting in low recovery percentages. Similarly, in the current
study increasing the amount of chitosan in formulation decreases the
process yield. F1 having chitosan to drug ratio 1.5: 1 showed process
yield of 49% in contrast to F2 having 1:1 ratio with process yield 57.3%,
Table 2.
The selection of solvent also affects the process yield. Furazoli-
done being poorly water soluble drug was not completely dissolved
when only distilled water was used as solvent before spray drying
in case of formulation F3 that gave 44.3% process yield. However
the yield was increased in F1 and F2 shown in Table 2, when drug
was ﬁrst dissolved in acetonitrile to make it completely soluble.
The use of co-solvent described by other studies bring two possibili-
ties; solvent facilitates evaporation process that in turn decreases the
time and energy required and shows positive effect on the percent-
age recovery [13]. It was reported that selection of solvent type inﬂu-
ences the structure of resultant microparticles which inﬂuences
different characteristics [14].
Similarly, drug content of microparticles wasmost probably affected
by the selection of solvent i.e. in F1 and F2when acetonitrilewas used as
co-solvent with distilled water the drug content was 60 and 66.6%
respectively. But in case of F3 when distilled water was only used as
solvent drug content was only 51% as shown in Table 2. Regarding
particle morphology, the microparticles were sphere and smooth as
shown in Fig. 1, but the morphology of microspheres with low concen-
tration of glutaraldehyde showed slightly wrinkled and somewhat
distorted surface.5.2. Mucin adsorption/mucoadhesion
H. pylori inhabitates in themucosal layer of the stomach and not in
the deeper muscluaris and serosal layer, and because the major com-
ponent of stomach mucosa is mucin therefore this study was con-
ducted on mucin to investigate mucin adsorption characteristics of
spray dried furazolidone-chitosan microparticles at two different
pHs. The amount of chitosan microparticles adsorbed on mucin was
determined indirectly by measuring the concentration of free
mucin after reaction between chitosan and mucin at different time
intervals. The crosslinking agent shown the negative effect on
mucin adsorption as depicted by the Fig. 2. The possible explanation
could be that, increasing glutaraldehyde concentration make micro-
particles harder which consequently decrease the percentage of
mucin adhesion ascribed in another study [15]. In the current
study, at pH 4.5 the formulation F1 having lowest amount of glutar-
aldehyde attain the maximum adsorption after 4 h, and then became
steady. However 50%was achieved in ﬁrst 2 h. In contrast, the formu-
lation F2 achieves 50% after 3 h and could maximally reach to 87% in
6 h. Formulation F3 with highest amount of glutaraldehyde attained
50% at fourth hour and shown maximum adsorption of 75% after 6 h
as shown in Fig. 2a. However, at pH 1.3 similar formulations demon-
strated different adhesion behavior. In current study the decrease in
the pH value, decrease the amount of the mucin adsorbed, results
shown in Fig. 2b; this fact ascribed in other studies [16,17], that acid-
ic environment had negative inﬂuence on the adsorption of mucin.
At pH 1.3 F1 gave only 7% adhesion in 2 h and maximally reached
to 60%. However, F2 and F3 the adhesion was very low after 2 h
and hardly achieved 50% after 6 h as shown in Fig. 2b. The results
at two different pH levels were signiﬁcant (p b 0.05). Similarly, var-
iable amount of crosslinking agent also has signiﬁcant impact on
mucin adsorption.5.3. In-vitro drug release
In vitro drug release of microparticles are shown in Fig. 3. Results
showed that release was increase by decreasing pH F1 released 91% of
drug after 5 h at pH 1.3, however the same formulation released only
73% at pH 4.5. Similarly, F2 and F3 released 76% and 79% of drug respec-
tively at pH 1.3 while the release was 62% and %51% at pH 4.5 as shown
in Fig. 3. Chitosan used as a polymer for microparticles becomes soluble
under low pH condition due to protonation of amino group that leads to
increase the release of drug at lower pH [18]; itwas reported thatmicro-
spheres almost released all entrapped drug at pH 1.2, however, nearly
70% of the drug was released over 3 h at pH 3.0 [18]. These results are
in agreement with the current study showing that increase in pH
leads to slower release of the drug.
The other factor that inﬂuenced the release rate is the concentration
of crosslinking agent (glutaraldehyde). Formulation that contained
higher concentration of glutaraldehyde (Table 1), showed less amount
of drug release as shown in Fig. 3; these results are in agreement with
a study by He et al. [10] that showed by increasing glutaraldehyde the
release was reduced. The effect of both pH and crosslinking agent
have signiﬁcant impact on release from zero time till ﬁve hours' time.
All the formulation at both pH levels demonstrated zero order kinet-
ics as the squared correlation coefﬁcient values of zero order kinetics are
higher than those of ﬁrst order kinetic (Table 3) . Zero order release
model describes the system where the rate of drug release is indepen-
dent of its concentration and the data are designed as the amount of
drug released against time [19].6. Conclusion
This study demonstrated thatmucoadhesive furazolidonemicropar-
ticles were successfully prepared by spray drying process. Those parti-
cles showed better adherence to mucin at low acidic condition
(pH 4.5), this favors the local gastric delivery of furazolidone against
Fig. 3. In-vitro drug release of furazolidone-chitosan microparticle formulations at a) pH 4.5 and b) pH 1.3. For formulation composition refer to Table 1.
179M.I. Alam et al. / Powder Technology 295 (2016) 175–179for exampleH. pyloriwhich increases gastric pH. At pH 4.5, formulations
F1, F2 and F3 accomplished 50%mucin adsorption after 2 h, 3 h and 4 h,
respectively. Therefore, this research is worth considering future in vivo
study.
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